Human parvovirus 4 in the blood supply and transmission by pooled plasma-derived clotting factors: Does it matter?

Transfusion

Volumn 52, Issue 7, 2012, Pages 1398-1403

  Delwart, Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; PROTEIN VP1; VIRUS DNA;

BLOOD DONOR; BLOOD TRANSFUSION; DNA DETERMINATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN PARVOVIRUS 4; HUMAN PARVOVIRUS B19; NONHUMAN; PARVOVIRUS; PARVOVIRUS INFECTION; POLYMERASE CHAIN REACTION; REVIEW; SEROPREVALENCE; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS INACTIVATION; VIRUS LOAD; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANTIBODIES, VIRAL; BLOOD COAGULATION FACTORS; FEMALE; HEMOPHILIA A; HUMANS; MALE; PARECHOVIRUS; PICORNAVIRIDAE INFECTIONS; VIRUS INACTIVATION;

EID: 84863799459     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03721.x     Document Type: Review

References (72)

1. Sharp CP, Lail A, Donfield S, Gomperts ED, Simmonds P,. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion 2012; 52: 1482-9.
2. Young NS, Brown KE,. Parvovirus B19. N Engl J Med 2004; 350: 586-97.
3. Brown KE,. The expanding range of parvoviruses which infect humans. Rev Med Virol 2010; 20: 231-44.
4. Parsyan A, Candotti D,. Human erythrovirus B19 and blood transfusion - an update. Transfus Med 2007; 17: 263-78.
5. Slavov SN, Kashima S, Pinto AC, Covas DT,. Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions. FEMS Immunol Med Microbiol 2011; 62: 247-62.
6. Kleinman SH, Glynn SA, Lee TH, Tobler LH, Schlumpf KS, Todd DS, Qiao H, Yu MY, Busch MP,; National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II (NHLBI REDS-II). A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009; 114: 3677-83.
7. Satake M, Hoshi Y, Taira R, Momose SY, Hino S, Tadokoro K,. Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion 2011; 51: 1887-95.
8. Dodd RY,. B19: benign or not? Transfusion 2011; 51: 1878-9.
9. Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E,. New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005; 79: 8230-6.
10. Sharp CP, LeBreton M, Kantola K, Nana A, Diffo Jle D, Djoko CF, Tamoufe U, Kiyang JA, Babila TG, Ngole EM, Pybus OG, Delwart E, Delaporte E, Peeters M, Soderlund-Venermo M, Hedman K, Wolfe ND, Simmonds P,. Widespread infection with homologues of human parvoviruses B19, PARV4, and human bocavirus of chimpanzees and gorillas in the wild. J Virol 2010; 84: 10289-96.
11. Canuti M, Eis-Huebinger AM, Deijs M, de Vries M, Drexler JF, Oppong SK, Müller MA, Klose SM, Wellinghausen N, Cottontail VM, Kalko EK, Drosten C, van der Hoek L,. Two novel parvoviruses in frugivorous New and Old World bats. PLoS ONE 2011; 6: e29140.
12. Tse H, Tsoi HW, Teng JL, Chen XC, Liu H, Zhou B, Zheng BJ, Woo PC, Lau SK, Yuen KY,. Discovery and genomic characterization of a novel ovine partetravirus and a new genotype of bovine partetravirus. PLoS ONE 2011; 6: e25619.
13. Adlhoch C, Kaiser M, Ellerbrok H, Pauli G,. High prevalence of porcine Hokovirus in German wild boar populations. Virol J 2010; 7: 171.
14. Lau SK, Woo PC, Tse H, Fu CT, Au WK, Chen XC, Tsoi HW, Tsang TH, Chan JS, Tsang DN, Li KS, Tse CW, Ng TK, Tsang OT, Zheng BJ, Tam S, Chan KH, Zhou B, Yuen KY,. Identification of novel porcine and bovine parvoviruses closely related to human parvovirus 4. J Gen Virol 2008; 89: 1840-8.
15. Fryer JF, Delwart E, Hecht FM, Bernardin F, Jones MS, Shah N, Baylis SA,. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion 2007; 47: 1054-61.
16. Fryer JF, Kapoor A, Minor PD, Delwart E, Baylis SA,. Novel parvovirus and related variant in human plasma. Emerg Infect Dis 2006; 12: 151-4.
17. Lurcharchaiwong W, Chieochansin T, Payungporn S, Theamboonlers A, Poovorawan Y,. Parvovirus 4 (PARV4) in serum of intravenous drug users and blood donors. Infection 2008; 36: 488-91.
18. Servant-Delmas A, Laperche S, Mercier M, Elghouzzi MH, Lionnet F, Stankovic K, Girot R, Lefrère JJ,. Human parvovirus 4 in recipients of cellular products and in blood donors: epidemiologic similarity with B19 parvovirus. Transfusion 2009; 49: 1771-3.
19. Fryer JF, Delwart E, Bernardin F, Tuke PW, Lukashov VV, Baylis SA,. Analysis of two human parvovirus PARV4 genotypes identified in human plasma for fractionation. J Gen Virol 2007; 88: 2162-7.
20. Ma YY, Guo Y, Zhao X, Wang Z, Lv MM, Yan QP, Zhang JG,. Human parvovirus PARV4 in plasma pools of Chinese origin. Vox Sang 2012 Mar 27. [Epub ahead of print]
21. Fryer JF, Hubbard AR, Baylis SA,. Human parvovirus PARV4 in clotting factor VIII concentrates. Vox Sang 2007; 93: 341-7.
22. Schneider B, Fryer JF, Oldenburg J, Brackmann HH, Baylis SA, Eis-Hübinger AM,. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Haemophilia 2008; 14: 978-86.
23. Szelei J, Liu K, Li Y, Fernandes S, Tijssen P,. Parvovirus 4-like virus in blood products. Emerg Infect Dis 2010; 16: 561-4.
24. Tuke PW, Parry RP, Appleton H,. Parvovirus PARV4 visualization and detection. J Gen Virol 2010; 91: 541-4.
25. Corcioli F, Zakrzewska K, Fanci R, De Giorgi V, Innocenti M, Rotellini M, Di Lollo S, Azzi A,. Human parvovirus PARV4 DNA in tissues from adult individuals: a comparison with human parvovirus B19 (B19V). Virol J 2010; 7: 272.
26. Longhi E, Bestetti G, Acquaviva V, Foschi A, Piolini R, Meroni L, Magni C, Antinori S, Parravicini C, Corbellino M,. Human parvovirus 4 in the bone marrow of Italian patients with AIDS. AIDS 2007; 21: 1481-3.
27. Manning A, Willey SJ, Bell JE, Simmonds P,. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. J Infect Dis 2007; 195: 1345-52.
28. Schneider B, Fryer JF, Reber U, Fischer HP, Tolba RH, Baylis SA, Eis-Hübinger AM,. Persistence of novel human parvovirus PARV4 in liver tissue of adults. J Med Virol 2008; 80: 345-51.
29. Botto S, Bergallo M, Sidoti F, Terlizzi ME, Astegiano S, Ponti R, Costa C, Cavallo R,. Detection of PARV4, genotypes 1 and 2, in healthy and pathological clinical specimens. New Microbiol 2009; 32: 189-92.
30. Touinssi M, Brisbarre N, Picard C, Frassati C, Dussol B, Uch R, Gallian P, Cantaloube JF, Micco P, Biagini P,. Parvovirus 4 in blood donors, France. Emerg Infect Dis 2010; 16: 165-6.
31. Touinssi M, Reynaud-Gaubert M, Gomez C, Thomas P, Dussol B, Berland Y, Basire A, Picard C, Cantaloube JF, de Micco P, Biagini P,. Parvovirus 4 in French in-patients: a study of hemodialysis and lung transplant cohorts. J Med Virol 2011; 83: 717-20.
32. Yu X, Zhang J, Hong L, Wang J, Yuan Z, Zhang X, Ghildyal R,. High prevalence of human parvovirus 4 infection in HBV and HCV infected individuals in Shanghai. PLoS ONE 2012; 7: e29474.
33. Panning M, Kobbe R, Vollbach S, Drexler JF, Adjei S, Adjei O, Drosten C, May J, Eis-Hubinger AM,. Novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg Infect Dis 2010; 16: 1143-6.
34. Simmonds P, Douglas J, Bestetti G, Longhi E, Antinori S, Parravicini C, Corbellino M,. A third genotype of the human parvovirus PARV4 in sub-Saharan Africa. J Gen Virol 2008; 89: 2299-302.
35. Norja P, Hokynar K, Aaltonen LM, Chen R, Ranki A, Partio EK, Kiviluoto O, Davidkin I, Leivo T, Eis-Hübinger AM, Schneider B, Fischer HP, Tolba R, Vapalahti O, Vaheri A, Söderlund-Venermo M, Hedman K,. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci U S A 2006; 103: 7450-3.
36. Matsukura H, Shibata S, Tani Y, Shibata H, Furuta RA,. Persistent infection by human parvovirus B19 in qualified blood donors. Transfusion 2008; 48: 1036-7.
37. Lefrère JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, Lefrère F, Girot R, Allain JP, Laperche S,. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005; 106: 2890-5.
38. Cassinotti P, Siegl G,. Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur J Clin Microbiol Infect Dis 2000; 19: 886-7.
39. Kleinman SH, Glynn SA, Lee TH, Tobler L, Montalvo L, Todd D, Kiss JE, Shyamala V, Busch MP,; National Heart, Lung, Blood Institute Retrovirus Epidemiology Donor Study (REDS-II). Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion 2007; 47: 1756-64.
40. Simmons R, Sharp C, Sims S, Kloverpris H, Goulder P, Simmonds P, Bowness P, Klenerman P,. High frequency, sustained T cell responses to PARV4 suggest viral persistence in vivo. J Infect Dis 2011; 203: 1378-87.
41. Simmonds P, Manning A, Kenneil R, Carnie FW, Bell JE,. Parenteral transmission of the novel human parvovirus PARV4. Emerg Infect Dis 2007; 13: 1386-8.
42. Truyen U,. Emergence and recent evolution of canine parvovirus. Vet Microbiol 1999; 69: 47-50.
43. Hoelzer K, Parrish CR,. The emergence of parvoviruses of carnivores. Vet Res 2010; 41: 39.
44. Fryer JF, Lucas SB, Padley D, Baylis SA,. Parvoviruses PARV4/5 in hepatitis C virus-infected patient. Emerg Infect Dis 2007; 13: 175-6.
45. Sharp CP, Lail A, Donfield S, Simmons R, Leen C, Klenerman P, Delwart E, Gomperts ED, Simmonds P,. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis 2009; 200: 1119-25.
46. Simmons R, Sharp C, McClure CP, Rohrbach J, Kovari H, Frangou E, Simmonds P, Irving W, Rauch A, Bowness P, Klenerman P,; the Swiss HIV Cohort Study. PARV4 infection and clinical outcome in high-risk populations. J Infect Dis 2012 Mar 3. [Epub ahead of print]
47. Yang SJ, Hung CC, Chang SY, Lee KL, Chen MY,. Immunoglobulin G and M antibodies to human parvovirus 4 (PARV4) are frequently detected in patients with HIV-1 infection. J Clin Virol 2011; 51: 64-7.
48. Lavoie M, Sharp CP, Pépin J, Pennington C, Foupouapouognigni Y, Pybus OG, Njouom R, Simmonds P,. Human parvovirus 4 infection, Cameroon. Emerg Infect Dis 2012; 18: 680-3.
49. Chen MY, Yang SJ, Hung CC,. Placental transmission of human parvovirus 4 in newborns with hydrops, Taiwan. Emerg Infect Dis 2011; 17: 1954-6.
50. Kapoor A, Simmonds P, Slikas E, Li L, Bodhidatta L, Sethabutr O, Triki H, Bahri O, Oderinde BS, Baba MM, Bukbuk DN, Besser J, Bartkus J, Delwart E,. Human bocaviruses are highly diverse, dispersed, recombination prone, and prevalent in enteric infections. J Infect Dis 2010; 201: 1633-43.
51. Kantola K, Hedman L, Allander T, Jartti T, Lehtinen P, Ruuskanen O, Hedman K, Söderlund-Venermo M,. Serodiagnosis of human bocavirus infection. Clin Infect Dis 2008; 46: 540-6.
52. Sharp CP, Vermeulen M, Nebie Y, Djoko CF, Lebreton M, Tamoufe U, Rimoin AW, Kayembe PK, Carr JK, Servant-Delmas A, Laperche S, Harrison GL, Pybus OG, Delwart E, Wolfe ND, Saville A, Lefrère JJ, Simmonds P,. Epidemiology of human parvovirus 4 infection in sub-Saharan Africa. Emerg Infect Dis 2010; 16: 1605-7.
53. Benjamin LA, Lewthwaite P, Vasanthapuram R, Zhao G, Sharp C, Simmonds P, Wang D, Solomon T,. Human parvovirus 4 as potential cause of encephalitis in children, India. Emerg Infect Dis 2011; 17: 1484-7.
54. Lahtinen A, Kivelä P, Hedman L, Kumar A, Kantele A, Lappalainen M, Liitsola K, Ristola M, Delwart E, Sharp C, Simmonds P, Söderlund-Venermo M, Hedman K,. Serodiagnosis of primary infections with human parvovirus 4, Finland. Emerg Infect Dis 2011; 17: 79-82.
55. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
56. Bernardin F, Operskalski E, Busch M, Delwart E,. Transfusion transmission of highly prevalent commensal human viruses. Transfusion 2010; 50: 2474-83.
57. Okamoto H,. History of discoveries and pathogenicity of TT viruses. Curr Top Microbiol Immunol 2009; 331: 1-20.
58. Hino S, Miyata H,. Torque teno virus (TTV): current status. Rev Med Virol 2007; 17: 45-57.
59. Cossart YE, Field AM, Cant B, Widdows D,. Parvovirus-like particles in human sera. Lancet 1975; 1: 72-3.
60. Cossart Y,. Parvovirus B19 finds a disease. Lancet 1981; 2: 988-9.
61. Serjeant GR, Topley JM, Mason K, Serjeant BE, Pattison JR, Jones SE, Mohamed R,. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet 1981; 2: 595-7.
62. Colmegna I, Alberts-Grill N,. Parvovirus B19: its role in chronic arthritis. Rheum Dis Clin North Am 2009; 35: 95-110.
63. Sancho-Shimizu V, de Diego RP, Jouanguy E, Zhang SY, Casanova JL,. Inborn errors of anti-viral interferon immunity in humans. Curr Opin Virol 2011; 1: 487-96.
64. Goodrich RP, Custer B, Keil S, Busch M,. Defining "adequate" pathogen reduction performance for transfused blood components. Transfusion 2010; 50: 1827-37.
65. Goodrich RP, Ettinger A, Radziwon PM, Rock G,. Improving blood safety and patient outcomes with pathogen reduction technology. Transfus Apher Sci 2011; 45: 229-38.
66. Goodrich RP, Edrich RA, Li J, Seghatchian J,. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17.
67. Ludlam CA, Powderly WG, Bozzette S, Diamond M, Koerper MA, Kulkarni R, Ritchie B, Siegel J, Simmonds P, Stanley S, Tapper ML, von Depka M,. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet 2006; 367: 252-61.
68. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY,. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 Suppl 2: 1S-29S.
69. Sejvar JJ,. The evolving epidemiology of viral encephalitis. Curr Opin Neurol 2006; 19: 350-7.
70. Alter HJ, Stramer SL, Dodd RY,. Emerging infectious diseases that threaten the blood supply. Semin Hematol 2007; 44: 32-41.
71. Dodd RY,. Current risk for transfusion transmitted infections. Curr Opin Hematol 2007; 14: 671-6.
72. Dunstan RA, Seed CR, Keller AJ,. Emerging viral threats to the Australian blood supply. Aust N Z J Public Health 2008; 32: 354-60.